Skip to main content
Erschienen in: Medical Oncology 3/2012

01.09.2012 | Original Paper

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial

verfasst von: Jean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, Pere Gascon, Carsten Bokemeyer, Heinz Ludwig, Jan Vermorken, Jason Legg, Beatriz Pujol, Ken Bridges

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA). Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin (Hb) levels <10 g/dL (US) or ≤10 g/dL (EU). The present exploratory analysis of a DA trial examined how baseline-Hb levels at ESA initiation affect transfusion rates, Hb response, and safety outcomes in CIA patients. Data were retrospectively analyzed from a phase 3 trial of CIA patients randomised to 500 mcg DA every 3 weeks (Q3 W) or to 2.25 mcg/kg DA weekly (QW) for 15 weeks. In the current analysis, data were reanalyzed by baseline-Hb categories of <9 g/dL (n = 126), 9 to <10 g/dL (n = 225), and ≥10 g/dL (n = 354). The Q3 W and QW groups were combined. Transfusion rates were highest in the <9 g/dL baseline-Hb group in all time periods examined. The Kaplan–Meier percentage (95% CI) of patients achieving Hb ≥10 g/dL was 68% (59, 78) and 88% (82, 92) in the <9 g/dL and 9 to <10 g/dL baseline-Hb groups, respectively. With lower baseline-Hb, incidence of a ≥1 g/dL-Hb rise in 14 days progressively decreased. Incidence of venous thromboembolic events was similar in all baseline-Hb groups and similar between patients with or without a ≥1 g/dL-Hb rise in 14 days. Overall, transfusion risk increased and Hb response decreased at lower baseline-Hb levels in this exploratory analysis. When following ESA-product information to initiate ESAs at Hb ≤ 10 g/dL, the greatest benefit may be achieved when initiating close to 10 g/dL. Prospective studies are needed to further examine this hypothesis.
Literatur
1.
Zurück zum Zitat Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–34.PubMedCrossRef Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–34.PubMedCrossRef
2.
Zurück zum Zitat Rodgers GM, et al. National comprehensive cancer network. Clinical practice guidelines in oncology: cancer- and treatment-related anemia. v.2.2011 ed; Available at: http://www.nccn.org. Accessed 18 June 2011. Rodgers GM, et al. National comprehensive cancer network. Clinical practice guidelines in oncology: cancer- and treatment-related anemia. v.2.2011 ed; Available at: http://​www.​nccn.​org. Accessed 18 June 2011.
3.
Zurück zum Zitat Birgegard G, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1):3–11.PubMedCrossRef Birgegard G, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1):3–11.PubMedCrossRef
4.
Zurück zum Zitat Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–38.PubMedCrossRef Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–38.PubMedCrossRef
5.
Zurück zum Zitat Ludwig H, Strasser K. Symptomatology of anemia. Sem Oncol. 2001;28:7–14.CrossRef Ludwig H, Strasser K. Symptomatology of anemia. Sem Oncol. 2001;28:7–14.CrossRef
6.
Zurück zum Zitat Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol. 2004;80:311–6.PubMedCrossRef Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol. 2004;80:311–6.PubMedCrossRef
7.
Zurück zum Zitat Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest. 2004;126:249–58.PubMedCrossRef Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest. 2004;126:249–58.PubMedCrossRef
8.
Zurück zum Zitat Khorana AA, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168:2377–81.PubMedCrossRef Khorana AA, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168:2377–81.PubMedCrossRef
9.
Zurück zum Zitat Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;CD005033. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;CD005033.
10.
Zurück zum Zitat Aranesp® (Darbepoetin alfa) package insert. Amgen Inc. Thousand Oaks, CA; 2010. Aranesp® (Darbepoetin alfa) package insert. Amgen Inc. Thousand Oaks, CA; 2010.
11.
Zurück zum Zitat Aranesp® (Darbepoetin alfa) package insert. Amgen Inc. Breda, The Netherlands. 2010. Aranesp® (Darbepoetin alfa) package insert. Amgen Inc. Breda, The Netherlands. 2010.
12.
Zurück zum Zitat Hedenus M, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403.PubMedCrossRef Hedenus M, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403.PubMedCrossRef
13.
Zurück zum Zitat Vansteenkiste J, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–20.PubMedCrossRef Vansteenkiste J, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–20.PubMedCrossRef
14.
Zurück zum Zitat Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol. 1998;15(Suppl 1):S47–9.PubMed Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol. 1998;15(Suppl 1):S47–9.PubMed
15.
Zurück zum Zitat Charu V, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007;12:1253–63.PubMedCrossRef Charu V, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007;12:1253–63.PubMedCrossRef
16.
Zurück zum Zitat Crawford J, Robert F, Perry MC, Belani C, Williams D. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007;2:210–20.PubMedCrossRef Crawford J, Robert F, Perry MC, Belani C, Williams D. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007;2:210–20.PubMedCrossRef
17.
Zurück zum Zitat Straus DJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006;107:1909–17.PubMedCrossRef Straus DJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006;107:1909–17.PubMedCrossRef
18.
Zurück zum Zitat Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006;106:223–33.PubMedCrossRef Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006;106:223–33.PubMedCrossRef
19.
Zurück zum Zitat Schouwink JH, Codrington H, Sleeboom HP, Kerkhofs LG, Wormhoudt LW. Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy. Eur J Cancer. 2008;44:819–29.PubMedCrossRef Schouwink JH, Codrington H, Sleeboom HP, Kerkhofs LG, Wormhoudt LW. Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy. Eur J Cancer. 2008;44:819–29.PubMedCrossRef
20.
Zurück zum Zitat Glaspy JA, et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009;115:1121–31.PubMedCrossRef Glaspy JA, et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009;115:1121–31.PubMedCrossRef
21.
Zurück zum Zitat Bohlius J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst. 2006;98:708–14.PubMedCrossRef Bohlius J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst. 2006;98:708–14.PubMedCrossRef
22.
Zurück zum Zitat Glaspy J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301–15.PubMedCrossRef Glaspy J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301–15.PubMedCrossRef
23.
Zurück zum Zitat Bohlius J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–42.PubMedCrossRef Bohlius J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–42.PubMedCrossRef
24.
Zurück zum Zitat Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.PubMedCrossRef Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.PubMedCrossRef
25.
Zurück zum Zitat Tonelli M, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62–71.PubMedCrossRef Tonelli M, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62–71.PubMedCrossRef
29.
Zurück zum Zitat Canon JL, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98:273–84.PubMedCrossRef Canon JL, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98:273–84.PubMedCrossRef
30.
Zurück zum Zitat Vansteenkiste J, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC cancer. 2009;9:311. Vansteenkiste J, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC cancer. 2009;9:311.
31.
Zurück zum Zitat Singh AK. The FDA’s perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010;5:553–6.PubMedCrossRef Singh AK. The FDA’s perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010;5:553–6.PubMedCrossRef
32.
Zurück zum Zitat Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol. 2009;27:4217–26.PubMedCrossRef Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol. 2009;27:4217–26.PubMedCrossRef
33.
Zurück zum Zitat Fandrey J, Dicato M. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist. 2009;14(Suppl 1):34–42.PubMedCrossRef Fandrey J, Dicato M. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist. 2009;14(Suppl 1):34–42.PubMedCrossRef
34.
Zurück zum Zitat Eisterer W, et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anaemic cancer patients receiving chemotherapy. Current Med Res Opin. 2011;27:355–63.CrossRef Eisterer W, et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anaemic cancer patients receiving chemotherapy. Current Med Res Opin. 2011;27:355–63.CrossRef
35.
Zurück zum Zitat Ludwig H, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838–47.PubMedCrossRef Ludwig H, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838–47.PubMedCrossRef
Metadaten
Titel
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial
verfasst von
Jean-Luc Canon
Johan Vansteenkiste
Michael Hedenus
Pere Gascon
Carsten Bokemeyer
Heinz Ludwig
Jan Vermorken
Jason Legg
Beatriz Pujol
Ken Bridges
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0103-x

Weitere Artikel der Ausgabe 3/2012

Medical Oncology 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.